Introduction

In 2010, the Parkinson’s disease market is estimated to generate $2.2bn across the seven major markets. As the market approaches maturity, Datamonitor forecasts growth to slow to a compound annual growth rate of 2.3% (2010-19), as pipeline entries partially offset the generic incursion of key brands.

Features and benefits

• Quantify the future (2010-19) size of the Parkinson’s disease market.
• Comprehensive epidemiology review of the Parkinson's disease market authored by trained epidemiologists.
• Review of the current Parkinson's disease drug dynamics, including detailed profiles.
• Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
• Analysis of current treatment approaches, patient acquisition and clinical unmet needs.

Highlights

The dopamine agonist Mirapex has been chosen as Datamonitor’s gold standard, on account of its tolerability and broad label for all severities of Parkinson’s disease. None of the pipeline drugs assessed are expected to replace Mirapex’s position over 2010–19.

Parkinson’s disease market growth is set to slump, as unimpressive pipeline launches will fail to offset generic incursion. The US market will experience a considerable drop in market share, from 29% in 2010 to 25% in 2019, as generics take hold.

New reformulations and the novel adenosine A2a receptor drugs do not offer the benefits or differentiation required to usurp existing drugs.

Your key questions answered

• What are the commercial prospects of current and potential therapies for Parkinson's disease over the next 10 years?
• How will the impact of recent patent expiries and new product launches affect the Parkinson’s disease market?
• How receptive is the market to new pipeline drugs and reformulations, in light of the availability of generic dopamine agonists?
• How will the new class of adenosine A2a receptior antagonists perform in the future marketplace?
• What are the current treatment approaches and unmet medical needs in Parkinson’s disease?